Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
28.42
-1.31 (-4.41%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Arcus Biosciences Revenue
Arcus Biosciences had revenue of $17.00M in the quarter ending March 31, 2026, a decrease of -39.29%. This brings the company's revenue in the last twelve months to $236.00M, up 67.38% year-over-year. In the year 2025, Arcus Biosciences had annual revenue of $247.00M, down -4.26%.
Revenue (ttm)
$236.00M
Revenue Growth
+67.38%
P/S Ratio
15.15
Revenue / Employee
$392,679
Employees
601
Market Cap
3.57B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 247.00M | -11.00M | -4.26% |
| Dec 31, 2024 | 258.00M | 141.00M | 120.51% |
| Dec 31, 2023 | 117.00M | 5.00M | 4.46% |
| Dec 31, 2022 | 112.00M | -271.00M | -70.76% |
| Dec 31, 2021 | 383.00M | 305.00M | 391.03% |
| Dec 31, 2020 | 78.00M | 63.00M | 420.00% |
| Dec 31, 2019 | 15.00M | 6.65M | 79.58% |
| Dec 31, 2018 | 8.35M | 6.94M | 491.15% |
| Dec 31, 2017 | 1.41M | - | - |
| Dec 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 803.79M |
| Arcutis Biotherapeutics | 415.62M |
| IDEAYA Biosciences | 225.27M |
| Tango Therapeutics | 56.99M |
| NewAmsterdam Pharma Company | 22.57M |
| Relay Therapeutics | 10.68M |
| Alumis | 8.40M |
RCUS News
- 2 days ago - Arcus, Summit enter into clinical trial collaboration over kidney cancer - TheFly
- 2 days ago - Arcus Biosciences announces clinical supply pact with AVEO Oncology - TheFly
- 2 days ago - Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients - Business Wire
- 2 days ago - Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer - Business Wire
- 2 days ago - Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer - Business Wire
- 3 days ago - Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates - Business Wire
- 4 days ago - Arcus Biosciences price target raised to $45 from $32 at H.C. Wainwright - TheFly
- 15 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire